NEW YORK – Roche said on Friday that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of its trastuzumab emtansine (Kadcyla) antibody-drug conjugate for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.